ReviewFrontiers in pharmacology2025
Bioactive metabolites of botanical drugs in the treatment of intervertebral disc degeneration-a review of promising therapeutic candidate.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intervertebral disc degeneration (IVDD) refers to the structural degeneration of intervertebral discs that occurs with aging or overuse, including annulus fibrosus rupture, nucleus pulposus dehydration, reduced proteoglycan content, and decreased elasticity. The bioactive metabolites of botanical drugs (BMBDs) refer to the chemical substances derived from plants that can exert specific physiological effects on living organisms, including the human body. Various types of the BMBDs regulate key protein targets and signaling pathways, demonstrating effects such as alleviating nucleus pulposus cell inflammation and oxidative stress levels, inhibiting extracellular matrix degradation, and regulating nucleus pulposus cell autophagy and apoptosis. Methods: All experimental information and summaries used in this review were acquired from peer-reviewed articles in the relevant fields. The PubMed, Web of Science (WOS), Google Scholar, and China National Knowledge Infrastructure (CNKI) databases were searched for relevant articles. Information on the manual classification and selection of BMBDs that protect against IVDD is included in this review. Results: The literature review identified multiple studies on the characteristics of BMBDs, which delay IVDD from various aspects through a wide range of key targets and signaling pathways. Conclusion: This review summarizes the pharmacological effects and mechanisms of different types of BMBDs in the treatment of IVDD, providing a theoretical foundation for further pharmacological research and the development of new drugs for treating IVDD, as well as strong theoretical support for future clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.